Quantum Biopharma (QNTM) Income towards Parent Company (2019 - 2026)
Quantum Biopharma recorded quarterly Income towards Parent Company of -$13.6 million in Q1 2026, down 435.67% quarter-over-quarter from -$2.5 million in Q4 2025, and down 58.11% year-over-year from -$32.4 million in Q1 2025.
Quantum Biopharma's Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$13.6 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 58.11% year-over-year to -$13.6 million; the TTM figure through Mar 2026 stood at -$30.7 million (down 74.14% YoY), while the FY2025 annual figure was -$15.5 million, changed N/A from the prior year.
- Income towards Parent Company came in at -$13.6 million for Q1 2026 at Quantum Biopharma, down from -$2.5 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$444506.0 in Q1 2022 to a low of -$13.6 million in Q1 2026.
- A 5-year average of -$5.3 million and a median of -$4.6 million in 2024 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company slumped 2140.13% in 2023 and soared 80.89% in 2024, its largest moves.
- Quantum Biopharma's Income towards Parent Company stood at -$444506.0 in 2022, then slumped by 1517.43% to -$7.2 million in 2023, then jumped by 70.88% to -$2.1 million in 2024, then dropped by 20.93% to -$2.5 million in 2025, then sank by 435.67% to -$13.6 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$13.6 million, -$2.5 million, and -$5.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.56 Mn |
| Dec 31, 2025 | -2.30 Mn |
| Sep 30, 2025 | -5.32 Mn |
| Jun 30, 2025 | -9.25 Mn |
| Mar 31, 2025 | -8.58 Mn |
| Dec 31, 2024 | -2.09 Mn |
| Sep 30, 2024 | -3.83 Mn |
| Jun 30, 2024 | -3.11 Mn |
| Mar 31, 2024 | -1.90 Mn |
| Dec 31, 2023 | -7.19 Mn |
| Sep 30, 2023 | -1.06 Mn |
| Jun 30, 2023 | -5.49 Mn |
| Mar 31, 2023 | -9.96 Mn |
| Mar 31, 2022 | -444,506.00 |
| Jun 30, 2021 | -452,937.00 |
| Mar 31, 2021 | 533,842.00 |
| Sep 30, 2020 | -1.16 Mn |
| Jun 30, 2020 | -408,872.15 |
| Mar 31, 2020 | -896,464.60 |
| Dec 31, 2019 | -11.59 Mn |
| Mar 31, 2019 | -849,800.46 |